ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer—Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study